Pseudohermafroditismo (HSC) su explicación y algunos comparativos con la persona transexual (página 3)

46. Kovacs J, Votava F, Heinze G,
Solyom J, Lebi J, Pribilincova Z, et al. Lessons from 30
years of clinical diagnosis and treatment of congenital
adrenal hyperplasia in five middle European countries. J Clin
Endocrinol Metab. 2001; 86: 2964—85.

47. Krone N, Arlt W. Genetics of
congenital adrenal hyperplasia. Best Pract Res Clin
Endocrinol Metab. 2009; 23: 181-92.

48. Kumar, H., Kiefer, J.H.,
Rosenthal, I.E., Clark, S.S.:"Clitoroplasty: experience
during a 19-fear period". J. Urol. 1974; 111: 81.

49. Labarta J, Bellos E,
Ruiz-Echarri M, Rueda C. Estado en la edad adulta y propuesta
de optimización terapeútica de la HSC. An
Pediatr. 2003;58( Supl2):12-34.

50. Lattimer, J.K.:"Relocation and
resection of the enlarged clítoris with preservation
of the glands: An alternative to amputation". J. Urol. 1961;
86: 113.

51. Leslie J DeGroot, J Larry
Jamenson, Endocrinology fourth edition. Volumen II Edition
2001

52. Levine LS, Zachmann M, New MI.
Genetic mapping of the 21-hydroxylase deficiency gene within
the HLA linkage group. N Engl J Med 1978; 299:
911.

53. Levine S. Hiperplasia
suprarrenal congénita. Pediatrics Review
2000;21:215-28.

54. Loriaux L. Glucocorticoid
therapy in the intensive care unit. N Engl J Med. 2004;
350:1601-2.

55. MacLaughlin DT, Donahoe PK.
Sex determination and differentiation.N Engl J Med 2004;
350(4):367-78.

56. Mah PM, Jenkins RC,
Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, et
al. Weight-related dosing, timing and monitoring
hydrocortisone replacement therapy in patients with
suprarrenal insufficiency. Clin Endocrinol. 2004; 61:
367-75.

57. Martínez MA.
Hernández BJ. Ramírez RCA, Esparza LH.
Hiperplasia suprarrenal congénita secundaria a
deficiencia de 21-hidroxilasa. Reporte de un caso. Bol Clin
Hosp Infant Endocrinol. 2007; 24(1):38-41.

58. Merke D, Borstein S.
Congenital adrenal hyperplasia. Lancet. 2005;365:
2125-36.

59. Merke D, Bortein SR, Avila NA.
Future directions in the study and management of congenital
adrenal hyperplasia due to 21 hydroxilase deficiency. Ann
Intern Med. 2002;136:320-34.

60. Migeon CJ, Wisniewwski AB.
Congenital adrenal hyperplasia swing21 hydroxilase
deficiency: growth, developmente and therapeutic
considerations. Endocrinol Metab Clin North Am. 2001;
30(1):193-206.

61. Miller WL, Levine LS.
Molecular and clinical advances in congenital adrenal
hyperplasia. J Pediatr 1987; 111: 1-13.

62. Miller WL. Genetics, diagnosis
and management of 21-hydroxylase deficiency. J Clin
Endocrinol Metab 1994; 78: 241-6.

63. Minagawa M, Yasuda T, Niimi H
J. Spinal and femoral bone mass accumulation during normal
adolescence: comparison with female patients with sexual
precocity and with hypogonadism.Clin Endocrinol Metab 1996;
81 (3): 1248-1253.

64. Muirhead S, Sellers EAC, Guyda
H. Indicatros of adult height outcome in classical
21-hidroxilase deficiency congenital adrenal hyperplasia. J
Pediatr. 2002; 141: 247-52.

65. New MI. Steroid 21-hydroxylase
deficiency (congenital adrenal hyperplasia). Am J Med 1995;
98 (Suppl 1A):2-8.

66. Niemann LK. Dynamic evaluation
of suprarrenal hypofunction. J Endocrinol Invest. 2003; 26 7
Suppl: 74-82.

67. Nieto Cuartero JA. Estados
intersexuales e hipogonadismo: anomalías de la
diferenciación gonadal. En: Libro Curso de
Formación Postgrado de la Sociedad Española de
Endocrinología Pediatrica;2001. p.
74—763.

68. Nimkarn S, New MI. Prenatal
diagnosis and treatment of congenital adrenal hyperplasia due
to 21-hydroxylase deficiency. Mol Cell Endocrinol. 2009;
300:192-6.

69. Oliver A, Ezquieta B, Gussinye
M. Hiperplasia suprarrenal congénita. En: Argente J,
Carrascosa A, editores. Tratado de Endocrinología
Pediátrica y de la Adolescencia. 2da ed. Barcelona;
2000. p. 995-1042.

70. Oliver A, Ezquieta B, Valera
JM. Estudio auxológico, bioquímico,
clínico y puberal en las formas no clásicas de
déficits de 21 hidroxilasa. Rev Horm Fact CECIM.
1999;4:1-8.

71. Orita M. Rapid and sensitive
detection of point mutations and DNA polymorphisms using the
polymerase chain reaction. Genomics1989; 5:
874-879.

72. Owerbach D, Sherman L, Ballard
AL, Azziz R. Pro-453 to Ser mutation in CYP21 is associated
with nonclassic steroid 21-hydroxylase deficiency. Mol
Endocrinol. 1992; 6: 1211-5.

73. Pang S, Wallace MA, Hofman L,
Thuline HC, Dorche C, Lyon IC T et al World-wide experience
in newborn screenning for classical congenital adrenal
hyperplasia due to 21-hydroxylase deficiency. Pediatrics
1988; 81: 866 -874.

74. Pang S. Congenital adrenal
hyperplasia. Endocrinol Metab Clin North Am 1997; 26:
853-91.

75. Parajes S, Quinteiro C,
Dominguez F, Loidi L. High frequency of copy number
variations and sequence variants at CYP21A2 locus:
implication for the genetic diagnosis of 21-hydroxylase
deficiency. PLoS ONE. 2008; 3: e2138.

76. Park KH, Lee SJ, Kim JY, Kim
JY, Bai SW, Kim JW. A concomitant decrease in cortical and
trabecular bone mass in isolated hypogonadotropic
hypogonadism and gonadal dysgenesis.

77. Parker KL. The roles of
steroidogenic factor 1 in endocrine development and function.
Mol Cell Endocrinol 1998;140(1-2):59-63

78. Peacey SR, Guo CY, Robinson
AM, Price A, Giles MA, Eastell R, et al. Glucocorticoid
replacement therapy: are patients overtreated and does it
matter? Clin Endocrinol. 1997; 46: 255-61.

79. Pesantes EL, López CC,
Robles UC, Valencia SG, Millonte GG. Hiperplasia Suprarrenal.
Revisión de 10 años en el Instituto Nacional de
Pediatría. Acta Pediatr Mex. 2000;
21:137-41.

80. Pinsky L. Androgen resistance
due to mutation of the androgen receptor. Clin Invest
Med1992; 15: 456-473.

81. Pombo M. Desarrollo Sexual y
Pubertad. En: Tratado de Endocrinología
Pediátrica. 3ra edi. Madrid: ESPAX; 2002. p.
719-42.

82. Quigley CA, De Bellis A,
Marschke K, El-Awadi MK, WilsonEM et al. Androgen Receptor
defects: Historical, clinical, and molecular perspectives.
Endocr Rev1995; 16: 271-321.

83. Relimpio A, Mangas C, Losada
V, Pumar L. Non-classical 21 hydroxilase deficiency:
clinico-hormonal discrepancies and intrafamiliar phenotypic
variability. Rev Clin Esp. 1999;199(6):366-8.

84. Rodríguez-Arnao MD,
Rodríguez A. Déficit de 21 hidroxilasa:
aspectos actuales. Endocrinol Nutr.
2006,53(2):124-36.

85. Seminara SB, Messager S,
Chatzidaki EE, Thresher RR, Acierno JS Jr, Shogoury JK, et
al. The GPR54 gene as a regulator of puberty. N Engl J Med.
2003; 349: 1614-27.

86. Sepúlveda Agudelo J.
Síndrome de hiperplasia adrenal congénita no
clásica y embarazo. Rev Chil Obstet Ginecol.
2003;68(1):28-31.

87. Sinnecker GH, Hiort O, Nitsche
EM, Holterhus P-M, Kruse K. Functional assesment and clinical
classification of androgen sensitivity in patients with
mutations of the androgen receptor gene. Eur J Pediatr1997:
156: 7-14.

88. Soriano Guillén L,
Velazquez de Cuellar Paracchi M. Hiperplasia Suprarrenal
Congénita. Pediatr Integral. 2007;XI
(7):601-10.

89. Speiser and White; Congenital
Adrenal Hyperplasia due to 21-Hydroxylase Deficiency;
Endocrine Reviews 21(3): 245-291; 2000

90. Speiser PW, Dupont B,
Rubinstein P, Piazza A, Kastelan A, New MI High frequency f
nonclassical steroid 21 -hydroxilase deficiency. Am J Hum
Genet, 1985; 37:650 -667.

91. Speiser PW, Dupont B,
Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of
nonclassical steroid 21-hydroxylase deficiency. Am J Hum
Genet 1985; 37: 650-67.

92. Speiser PW. Congenital adrenal
hyperplasia owing to 21-hydroxylase deficiency. Endocrinol
Metab Clin North Am 2001; 30:31-60.

93. Speiser PW. Congenital adrenal
hyperplasia owwing to 21 hydroxilase deficiency. Endocrinol
Metab Clin North Am. 2001; 30:31-60.

94. Spence, H.M., Hallen,
T.D.:"Genital reconstruction in the female with adrenogenital
syndrome". Brit. J. Urol. 1973; 45: 126.

95. Therrell BL. Newborn screening
for congenital adrenal hyperplasia. Endocrinol Metab Clin
North Am. 2001; 30: 15-30.

96. Wedel A. Molecular genetics of
congenital adrenal hyperplasia (21-hydroxilase deficiency):
implications for diagnosis, prognosis and treatment. Acta
Pediatr. 1998;87:159-64.

97. White PC, Speiser PW.
Congenital adrenal hyperplasia due to 21 hydroxilase
deficiency. Endocr Rev. 2000;21: 245-91.

98. White PC, Speiser PW. Long
term consequences of chilhood-onset congenital adrenal
hyperplasia. Best Pract Res Clin Endocrinol Metab. 2002;16:
273-88.

99. With PC, Speicer PW.
Congenital adrenal hyperplasia. Engl J Med. 2003;349:
766-8.